Good will Slide afternoon, Tarek. on you, begin everybody. XX. I Thank
an phase anemia. warm hemolytic Fostamatinib ongoing is As you three currently autoimmune know, in in trial pivotal
progress, our how on we adapting environment. are update current an this Here's and in
our of March half have patients had COVID-XX enrollment to temporarily XX momentum target the study, sites we which nearly pandemic until Currently, clinical into trials when recruiting and screening. widely, postpone early good number. randomized the We is begin very spread
the delaying of now, operational our effectively like is trials. importance I'd enrollment this While to foundation for the of emphasize established
soon sites on a should we We normalizes, situation quicker have basis, country-by-country countries trial which others, countries will over some regain momentum provide enrollment And likely and active. in than that competitive we a as efficiently. XX can to since the COVID-XX remain are quickly normalize enrollment Hence, XX advantage. as rather restart
we the FDA the program. conversations quarter, also with about had During productive the
with placebo. sample claimed patients. As is controlled randomization reminder, was one a to a Fostamatinib XX trial size one to be placebo to the Originally, the
could drug the powering working trial appropriate three, to FDA only usability measure. the most we slightly the phase patients, adds data with have the trial incremental we mitigate no Since finalizing We setting any FDA COVID-XX. the AIHA standards help have the to potential establishing We're approved AIHA there this in and by increased and still to size criterion. durability is the with work a are pivotal missing and on to study, XX caused which
we the FDA conduct Turning XX. to provided been COVID-XX COVID-XX in Rigel for industry, trials utilizing. others to to are pandemic. the phase Like rapidly three which of conduct provide guidance that Slide recently clinical flexibility adapt The our forced some during due has trial current the
can basic virus blood and small care local from be to so physicians get collect For them patient's the be or some analyzed by as have kept primary risk visits replaced can exposure the example, the virtual to lab site draws information can as possible. safety patients their of locally at visits
for study. focus on the a obtainable maintain already in sharp robust We also data set complete laser collecting that to maintain are order a patients all and the in
we will enrollment is clear on this delay. right Regarding now, completion, a there COVID-XX-related At what cannot time, exactly. give be the guidance delay
the COVID-XX as certain. more provide becomes global will updates impact We
earlier, to with enrollment mover geographical the for potentially that could have AHIA its large range our active. to we all alluded lead If advantages. extend our enrollment But treatment of should to as I this the have anything, first goal pause numbers the not market impact given first remain sites in our
Slide XX.
you pipeline in I to COVID-XX beyond additional for rationale slide, scientific little and and see options Moving COVID-XX the the Fostamatinib AIHA, will potential a to in on while. activities speak
to a for the our exclusivity we this potential in of Fostamatinib indications Executing broad expected full the considered program, into be take opportunities to of we XXXX. large the is on narrowed Given to and for have enable us additional an sick Fostamatinib will search to inhibition we the plan which for label indication molecule, pursue. pool most attractive down advantage which
TLR position. in of and has good and progress the both addition production achieves to preclinical receptor Fostamatinib signaling, studies, IRAKX and a block pathways of cytokine to to and human its inhibitor, proof In study program molecule to only one inhibitor demonstrate PK in continues family IRAKX In it phase IL-X remains characteristics. healthy shown one IRAKX volunteer mechanism inflammatory our its the response and favorable
our ascending multiple study the stage our I inhibitor. with completed of RIPX dose systemic recently we Finally, Phase
in a CNS clinical it the doses, half-life have as which allow move to and as range XX-hour identified these quite as safe should is We the plan identify once inhibitors into mentioned clinic And significant well. to is RIP expected within future confirmed also Importantly, near that we dose a we is for dosing. previously, day molecule well the for efficacy.
let Now, have in syndrome. considerations patients. COVID-XX to in truly treating and of associated the drug shift distress treatment as for use pneumonia, Fostamatinib of compelling scientific is there We briefly me our for share acute the respiratory the benefit well COVID-XX gears believe a as rationale
Let through that. me take you
XX. Slide
and low Severe can know, death. to really frequently The as oxygen and the to rapid through right, pneumonia the I not to that most pathology, mechanisms, the is progression cases a system of progress this Interestingly, the when decreases. actually complications walk load simplified the which in antibodies somewhat may pathway begun has ventilation system SARS-CoV-X already to against causes on just associated blood you severe COVID-XX. requires illustrated slide. means sick severe viral virus. you this. saturation invasive and As please ARDS one the is with immune image involved Look That at due happens often leads this the multiple immune make on
reduce organs the you damage SYK and highly inside DAMPs this damage-associated coagulopathy If from find by other destruction the and All look CLRS. to particle release causes which can cytokine also the excessive Signaling the process such called PAMPs as replicating toxicity a process. fostamatinib virus neutrophil cells vascular the at cells activation or events endothelial in molecular lead NETosis. these CLRS can inflammatory heart. and pathogen-associated inhibition receptors to and lung virus the patterns, massive epithelial kidneys of and through the so-called inflammatory to so-called early stages molecular can of patterns release infection, lung C-lectin and
you look main you for side if the hyper-reactive of Now, image, left second mechanism can system. immune a the see towards the
cells As a and then IL-X. FC such release viral make excessive form in as and the the cells systems immune complexes patients such antibodies. gamma response cytokines monocytes. virus our macrophages, inflammatory begin as dendritic IL-X with antibodies These to anti-SARS-CoV-X can which beta, virus induce infection, to receptor-expressing and That to IL-X binds some immune of find
and therefore damage. ARDS only damage, may organ multiple inhibition COVID-XX viral that pathology and with too, could ameliorate cytokine cell COVID-XX in SYK approved Fostamatinib other types can multiple of prevent SYK of storm the related the work points interfere pneumonia resulting is etiology. through and at also Here organ fostamatinib this inhibitor
model concept Now, do this have a is of new not preclinical as ARDS. we an entirely data from
On executive Slide those an XX, summary experiments. see you mouse of
active Here as model this fosta. fosta same the and used RXXX is metabolite the of essentially in
tissue into lung tissue left, circumstances. histology see oxygen where the see lung happens. you left, the alveoli the blood healthy transport with clear the On full different of you and Upper of
no thing when see administered fluid induced lots respiratory debris impact of in the insufficient. the LPS you and oxygenation the is top the on syndrome making looking or different inflammation, right, at lower with acute same fostamatinib only lungs. by the left, But which lead to of the see you alveoli, On massive negative cell distress blood
On the this survival right, panel on lower has fostamatinib pathology. effect right, as on mice with depicted to Not leads on fostamatinib. the of you that treated clear can surprisingly, the see a with that beneficial were the ARDS this
to all into It are initial potentially That contemplating trial. one to do drug trials righteous What mean the hospitals providing seriously way or with fostamatinib are investigator-sponsored one could some the more to we could the in of to to data. get sponsored all another. support mean or this? going generate currently We clinic form to a clinical
posted. you keep will We
With review that, Dean for I'll hand of the over financials. Dean? a to
